siRNA therapy

Twice-Yearly Inclisiran Transforms LDL-C Management in Adolescents with HeFH: Insights from ORION-16

The ORION-16 trial demonstrates that inclisiran, a twice-yearly siRNA therapy, significantly and safely reduces LDL cholesterol in adolescents with heterozygous familial hypercholesterolaemia, offering a promising solution for long-term adh